+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07493044

Phase I Trial of Super CAR-T Cell Therapy Targeting GPC3 for Advanced Liver Cancer Hepatocellular Carcinoma

Led by Guangzhou FineImmune Biotechnology Co., LTD. · Updated on 2026-05-14

15

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase I clinical trial to evaluate the safety and tolerability of a treatment called Super CAR-T in patients with advanced hepatocellular carcinoma HCC that tests positive for GPC3. This open-label, single-center study uses a 33 dose escalation design to find the appropriate dose. The trial focuses on patients with inoperable or advanced HCC who have previously failed or cannot tolerate standard therapies. Participants receive lymphodepleting preconditioning followed by a single infusion of Super CAR-T cells, which are designed to target GPC3-positive tumor cells. The dose of Super CAR-T cells is gradually increased across three levels to monitor toxicity. The trial includes screening to confirm GPC3 positivity in tumor tissue before treatment. During the study, participants will be monitored closely for dose-limiting toxicities and maximum tolerated dose within 28 days after infusion. Researchers will also assess tumor response, progression-free survival, and overall survival up to one year after treatment. Various tests including echocardiography, laboratory studies, and performance status evaluations are performed to ensure safety and track outcomes throughout the trial.

CONDITIONS

Brief Title

An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma

Research Team

Y

YING CHENG

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here